Showing results (191-200 of 261) with videos related to
Sort By:
Pageof 27
Parasite Immunology|February 1, 1997
The isolation of a 22 kDa band after SDS-PAGE of Schistosoma mansoni adult worms and its use to demonstrate that IgE responses against the antigen(s) it contains are associated with human resistance to reinfectionD W Dunne, M Webster, P Smith, et al.Journal of the American Academy of Dermatology|December 29, 2016
Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trialsKristian Reich, Craig Leonardi, Richard G Langley, et al.The British Journal of Dermatology|October 15, 2021
Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasisK B Gordon, M Lebwohl, K A Papp, et al.Behavioral Ecology : Official Journal of the International Society for Behavioral Ecology|August 22, 2020
Heritability and correlations among learning and inhibitory control traitsEllis J G Langley, Gracie Adams, Christine E Beardsworth, et al.Journal of Drugs in Dermatology : JDD|August 16, 2021
Serious Gastrointestinal-Related Adverse Events Among Psoriasis Patients Treated With Guselkumab in VOYAGE 1 and VOYAGE 2Peter Foley, Kristian Reich, Andrew Blauvelt, et al.Journal of the American Academy of Dermatology|April 29, 2005
Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studiesAmy S Paller, Mark Lebwohl, Alan B Fleischer, et al.The British Journal of Dermatology|October 14, 2014
Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-upR G Langley, M Lebwohl, G G Krueger, et al.Lancet (London, England)|May 20, 2008
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)Kim A Papp, Richard G Langley, Mark Lebwohl, et al.Dermatology and Therapy|May 14, 2026
Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 TrialRichard G Langley, Lisa Arkin, Loretta Fiorillo, et al.The New England Journal of Medicine|April 23, 2021
Bimekizumab versus Secukinumab in Plaque PsoriasisKristian Reich, Richard B Warren, Mark Lebwohl, et al.Pageof 27